The Prenatal and Newborn Genetic Testing Market was valued for $4,891.51 million in 2021 and is estimated to reach $14,727.30 million by 2031, exhibiting a CAGR of 11.5% from 2022 to 2031. Prenatal tests are the medical tests performed during pregnancy which consist of prenatal diagnosis and prenatal screening for detecting problems with pregnancy. It is offered during first or second trimester to women during pregnancy to determine whether the fetus has the possibility to be born with genetic diseases. Newborn testing is considered a public health service done in every U.S. state to diagnose genetic abnormalities in newly born babies. The early detection of genetic diseases may prevent more serious forms of genetic abnormalities and prevent parents from having a disabled child is the primary advantage of prenatal genetic testing. Some of the genetic testing methods include polymerase chain reaction (PCR), fluorescence in-situ hybridization, and array-comparative genomic hybridization.
The prenatal and newborn genetic testing market growth is driven by a rise in the incidence and prevalence of genetic diseases such as cystic fibrosis, Down’s syndrome, phenylketonuria, and others and rise in technological advancement in methods of prenatal and newborn genetic testing. The rise in the prevalence of genetic diseases propels high adoption of prenatal and newborn genetic testing for diagnosis of diseases. The National Library of Medicine estimated that phenylketonuria occurs in 1 in 10,000 newborns. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), in May 2022, sickle cell disease occurs in 1 out of 365 African and American births.
Furthermore, the rise in technological advancement is the key factor that boosts the market growth. For instance, in August 2022, F. Hoffmann-La Roche AG launched the Digital LightCycler System a next-generation digital PCR system that helps physicians to better understand the nature of genetic diseases. This system is designed for performing highly sensitive and precise RNA and DNA analysis.
However, the high cost of non-invasive prenatal testing (NIPT) and other diagnostic tests limits the adoption of prenatal and newborn genetic testing, which, in turn, restrains the market growth. For instance, chronic villus sampling costs around $3,050, and amniocentesis costs about $4,100 without insurance.
Increased medical demands in developed countries such as U.S., Canada, and Germany and growth opportunities in emerging markets, on the other hand, are expected to create immense opportunities for the prenatal and newborn genetic testing market during the forecast period. Moreover, a rise in awareness regarding the use of prenatal and newborn genetic testing for the diagnosis and monitoring of seizures is expected to propel the market growth during the forecast period.
The prenatal and newborn genetic testing market is segmented into product type, screening, disease, and end user. On the basis of product type, the market is bifurcated into instruments and consumables. On the basis of screening, the market is segmented into non-invasive prenatal testing (NIPT), chronic villus sampling (CVS), amniocentesis, maternal serum screening (MSS), and others. On the basis of disease, the market is categorized into Down’s syndrome, phenylketonuria, cystic fibrosis, sickle cell anemia, and others. On the basis of end users, the market is fragmented into hospitals, maternity and specialty clinics, and diagnostic centers.
On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the global Prenatal and newborn genetic testing Market are Bio-Rad Laboratories, Inc., PerkinElmer Inc., Natera, Inc., Quest Diagnostics Incorporated, F. Hoffmann-La Roche AG, Mettler Toledo, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Abbott Laboratories, and BGI Group.
The prenatal and newborn genetic testing market growth is driven by a rise in the incidence and prevalence of genetic diseases such as cystic fibrosis, Down’s syndrome, phenylketonuria, and others and rise in technological advancement in methods of prenatal and newborn genetic testing. The rise in the prevalence of genetic diseases propels high adoption of prenatal and newborn genetic testing for diagnosis of diseases. The National Library of Medicine estimated that phenylketonuria occurs in 1 in 10,000 newborns. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), in May 2022, sickle cell disease occurs in 1 out of 365 African and American births.
Furthermore, the rise in technological advancement is the key factor that boosts the market growth. For instance, in August 2022, F. Hoffmann-La Roche AG launched the Digital LightCycler System a next-generation digital PCR system that helps physicians to better understand the nature of genetic diseases. This system is designed for performing highly sensitive and precise RNA and DNA analysis.
However, the high cost of non-invasive prenatal testing (NIPT) and other diagnostic tests limits the adoption of prenatal and newborn genetic testing, which, in turn, restrains the market growth. For instance, chronic villus sampling costs around $3,050, and amniocentesis costs about $4,100 without insurance.
Increased medical demands in developed countries such as U.S., Canada, and Germany and growth opportunities in emerging markets, on the other hand, are expected to create immense opportunities for the prenatal and newborn genetic testing market during the forecast period. Moreover, a rise in awareness regarding the use of prenatal and newborn genetic testing for the diagnosis and monitoring of seizures is expected to propel the market growth during the forecast period.
The prenatal and newborn genetic testing market is segmented into product type, screening, disease, and end user. On the basis of product type, the market is bifurcated into instruments and consumables. On the basis of screening, the market is segmented into non-invasive prenatal testing (NIPT), chronic villus sampling (CVS), amniocentesis, maternal serum screening (MSS), and others. On the basis of disease, the market is categorized into Down’s syndrome, phenylketonuria, cystic fibrosis, sickle cell anemia, and others. On the basis of end users, the market is fragmented into hospitals, maternity and specialty clinics, and diagnostic centers.
On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the global Prenatal and newborn genetic testing Market are Bio-Rad Laboratories, Inc., PerkinElmer Inc., Natera, Inc., Quest Diagnostics Incorporated, F. Hoffmann-La Roche AG, Mettler Toledo, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Abbott Laboratories, and BGI Group.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the prenatal and newborn genetic testing market analysis from 2021 to 2031 to identify the prevailing prenatal and newborn genetic testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the prenatal and newborn genetic testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global prenatal and newborn genetic testing market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Product Type
- Consumables
- Instruments
By Screening
- Non-invasive Prenatal Testing
- Chronic Villus Sampling
- Amniocentesis
- Maternal Serum Screening
By Disease
- others
- Downs Syndrome
- Phenylketonuria
- Cystic Fibrosis
- Sickle Cell Anemia
By End User
- Hospital
- Maternity and Specialty Clinics
- Diagnostic centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bio-Rad Laboratories, Inc.
- Mettler Toledo
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- BGI Group
- PerkinElmer Inc.
- Natera, Inc.
- F. Hoffmann-La Roche AG
- Quest Diagnostics Incorporated
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. High threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of genetic diseases among infants
3.4.1.2. Rise in demand for non-invasive prenatal testing
3.4.2. Restraints
3.4.2.1. High cost of complex prenatal and newborn genetic testing
3.4.3. Opportunities
3.4.3.1. Lucrative growth opportunities in developing countries
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Instruments
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING
5.1. Overview
5.1.1. Market size and forecast
5.2. Non-invasive Prenatal Testing
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Chronic Villus Sampling
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Amniocentesis
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Maternal Serum Screening
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE
6.1. Overview
6.1.1. Market size and forecast
6.2. Downs Syndrome
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Phenylketonuria
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Cystic Fibrosis
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Sickle Cell Anemia
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Maternity and Specialty Clinics
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Diagnostic centers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product Type
8.2.3. Market size and forecast, by Screening
8.2.4. Market size and forecast, by Disease
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product Type
8.2.6.1.3. Market size and forecast, by Screening
8.2.6.1.4. Market size and forecast, by Disease
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product Type
8.2.6.2.3. Market size and forecast, by Screening
8.2.6.2.4. Market size and forecast, by Disease
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product Type
8.2.6.3.3. Market size and forecast, by Screening
8.2.6.3.4. Market size and forecast, by Disease
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product Type
8.3.3. Market size and forecast, by Screening
8.3.4. Market size and forecast, by Disease
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product Type
8.3.6.1.3. Market size and forecast, by Screening
8.3.6.1.4. Market size and forecast, by Disease
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product Type
8.3.6.2.3. Market size and forecast, by Screening
8.3.6.2.4. Market size and forecast, by Disease
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product Type
8.3.6.3.3. Market size and forecast, by Screening
8.3.6.3.4. Market size and forecast, by Disease
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product Type
8.3.6.4.3. Market size and forecast, by Screening
8.3.6.4.4. Market size and forecast, by Disease
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product Type
8.3.6.5.3. Market size and forecast, by Screening
8.3.6.5.4. Market size and forecast, by Disease
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product Type
8.3.6.6.3. Market size and forecast, by Screening
8.3.6.6.4. Market size and forecast, by Disease
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product Type
8.4.3. Market size and forecast, by Screening
8.4.4. Market size and forecast, by Disease
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product Type
8.4.6.1.3. Market size and forecast, by Screening
8.4.6.1.4. Market size and forecast, by Disease
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product Type
8.4.6.2.3. Market size and forecast, by Screening
8.4.6.2.4. Market size and forecast, by Disease
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product Type
8.4.6.3.3. Market size and forecast, by Screening
8.4.6.3.4. Market size and forecast, by Disease
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product Type
8.4.6.4.3. Market size and forecast, by Screening
8.4.6.4.4. Market size and forecast, by Disease
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product Type
8.4.6.5.3. Market size and forecast, by Screening
8.4.6.5.4. Market size and forecast, by Disease
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product Type
8.4.6.6.3. Market size and forecast, by Screening
8.4.6.6.4. Market size and forecast, by Disease
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product Type
8.5.3. Market size and forecast, by Screening
8.5.4. Market size and forecast, by Disease
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product Type
8.5.6.1.3. Market size and forecast, by Screening
8.5.6.1.4. Market size and forecast, by Disease
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product Type
8.5.6.2.3. Market size and forecast, by Screening
8.5.6.2.4. Market size and forecast, by Disease
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product Type
8.5.6.3.3. Market size and forecast, by Screening
8.5.6.3.4. Market size and forecast, by Disease
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product Type
8.5.6.4.3. Market size and forecast, by Screening
8.5.6.4.4. Market size and forecast, by Disease
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1. Bio-Rad Laboratories, Inc.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. PerkinElmer Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Natera, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Quest Diagnostics Incorporated
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. F. Hoffmann-La Roche AG
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Mettler Toledo
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Laboratory Corporation of America Holdings
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Thermo Fisher Scientific Inc.
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.9. Abbott Laboratories
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. BGI Group
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
List of Tables
Table 01. Global Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 02. Prenatal and Newborn Genetic Testing Market for Consumables, by Region, 2021-2031 (Revenue, $Million)
Table 03. Prenatal and Newborn Genetic Testing Market for Instruments, by Region, 2021-2031 (Revenue, $Million)
Table 04. Global Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 05. Prenatal and Newborn Genetic Testing Market for Non-Invasive Prenatal Testing, by Region, 2021-2031 (Revenue, $Million)
Table 06. Prenatal and Newborn Genetic Testing Market for Chronic Villus Sampling, by Region, 2021-2031 (Revenue, $Million)
Table 07. Prenatal and Newborn Genetic Testing Market for Amniocentesis, by Region, 2021-2031 (Revenue, $Million)
Table 08. Prenatal and Newborn Genetic Testing Market for Maternal Serum Screening, by Region, 2021-2031 (Revenue, $Million)
Table 09. Prenatal and Newborn Genetic Testing Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 10. Global Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 11. Prenatal and Newborn Genetic Testing Market for Downs Syndrome, by Region, 2021-2031 (Revenue, $Million)
Table 12. Prenatal and Newborn Genetic Testing Market for Phenylketonuria, by Region, 2021-2031 (Revenue, $Million)
Table 13. Prenatal and Newborn Genetic Testing Market for Cystic Fibrosis, by Region, 2021-2031 (Revenue, $Million)
Table 14. Prenatal and Newborn Genetic Testing Market for Sickle Cell Anemia, by Region, 2021-2031 (Revenue, $Million)
Table 15. Prenatal and Newborn Genetic Testing Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 16. Global Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 17. Prenatal and Newborn Genetic Testing Market for Hospital, by Region, 2021-2031 (Revenue, $Million)
Table 18. Prenatal and Newborn Genetic Testing Market for Maternity and Specialty Clinics, by Region, 2021-2031 (Revenue, $Million)
Table 19. Prenatal and Newborn Genetic Testing Market for Diagnostic Centers, by Region, 2021-2031 (Revenue, $Million)
Table 20. Prenatal and Newborn Genetic Testing Market, by Region, 2021-2031 (Revenue, $Million)
Table 21. North America Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 22. North America Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 23. North America Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 24. North America Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 25. North America Prenatal and Newborn Genetic Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 26. U.S. Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 27. U.S. Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 28. U.S. Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 29. U.S. Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 30. Canada Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 31. Canada Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 32. Canada Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 33. Canada Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 34. Mexico Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 35. Mexico Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 36. Mexico Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 37. Mexico Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 38. Europe Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 39. Europe Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 40. Europe Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 41. Europe Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 42. Europe Prenatal and Newborn Genetic Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 43. Germany Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 44. Germany Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 45. Germany Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 46. Germany Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 47. France Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 48. France Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 49. France Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 50. France Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 51. UK Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 52. UK Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 53. UK Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 54. UK Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 55. Italy Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 56. Italy Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 57. Italy Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 58. Italy Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 59. Spain Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 60. Spain Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 61. Spain Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 62. Spain Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 63. Rest of Europe Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 64. Rest of Europe Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 65. Rest of Europe Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 66. Rest of Europe Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 67. Asia-Pacific Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 68. Asia-Pacific Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 69. Asia-Pacific Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 70. Asia-Pacific Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 71. Asia-Pacific Prenatal and Newborn Genetic Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 72. Japan Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 73. Japan Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 74. Japan Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 75. Japan Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 76. China Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 77. China Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 78. China Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 79. China Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 80. Australia Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 81. Australia Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 82. Australia Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 83. Australia Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 84. India Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 85. India Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 86. India Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 87. India Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 88. South Korea Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 89. South Korea Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 90. South Korea Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 91. South Korea Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 92. Rest of Asia-Pacific Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 93. Rest of Asia-Pacific Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 94. Rest of Asia-Pacific Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 95. Rest of Asia-Pacific Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 96. LAMEA Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 97. LAMEA Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 98. LAMEA Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 99. LAMEA Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 100. LAMEA Prenatal and Newborn Genetic Testing Market, by Country, 2021-2031 (Revenue, $Million)
Table 101. Brazil Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 102. Brazil Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 103. Brazil Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 104. Brazil Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 105. Saudi Arabia Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 106. Saudi Arabia Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 107. Saudi Arabia Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 108. Saudi Arabia Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 109. South Africa Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 110. South Africa Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 111. South Africa Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 112. South Africa Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 113. Rest of LAMEA Prenatal and Newborn Genetic Testing Market, by Product Type, 2021-2031 (Revenue, $Million)
Table 114. Rest of LAMEA Prenatal and Newborn Genetic Testing Market, by Screening, 2021-2031 (Revenue, $Million)
Table 115. Rest of LAMEA Prenatal and Newborn Genetic Testing Market, by Disease, 2021-2031 (Revenue, $Million)
Table 116. Rest of LAMEA Prenatal and Newborn Genetic Testing Market, by End-user, 2021-2031 (Revenue, $Million)
Table 117. Bio-Rad Laboratories, Inc.: Key Executives
Table 118. Bio-Rad Laboratories, Inc.: Company Snapshot
Table 119. Bio-Rad Laboratories, Inc.: Product Segments
Table 120. Bio-Rad Laboratories, Inc.: Product Portfolio
Table 121. Perkinelmer Inc.: Key Executives
Table 122. Perkinelmer Inc.: Company Snapshot
Table 123. Perkinelmer Inc.: Product Segments
Table 124. Perkinelmer Inc.: Product Portfolio
Table 125. Perkinelmer Inc.: Key Strategies
Table 126. Natera, Inc.: Key Executives
Table 127. Natera, Inc.: Company Snapshot
Table 128. Natera, Inc.: Product Segments
Table 129. Natera, Inc.: Product Portfolio
Table 130. Quest Diagnostics Incorporated: Key Executives
Table 131. Quest Diagnostics Incorporated: Company Snapshot
Table 132. Quest Diagnostics Incorporated: Product Segments
Table 133. Quest Diagnostics Incorporated: Product Portfolio
Table 134. F. Hoffmann-La Roche AG: Key Executives
Table 135. F. Hoffmann-La Roche AG: Company Snapshot
Table 136. F. Hoffmann-La Roche AG: Product Segments
Table 137. F. Hoffmann-La Roche AG: Product Portfolio
Table 138. F. Hoffmann-La Roche AG: Key Strategies
Table 139. Mettler Toledo: Key Executives
Table 140. Mettler Toledo: Company Snapshot
Table 141. Mettler Toledo: Product Segments
Table 142. Mettler Toledo: Product Portfolio
Table 143. Laboratory Corporation of America Holdings: Key Executives
Table 144. Laboratory Corporation of America Holdings: Company Snapshot
Table 145. Laboratory Corporation of America Holdings: Product Segments
Table 146. Laboratory Corporation of America Holdings: Product Portfolio
Table 147. Thermo Fisher Scientific Inc.: Key Executives
Table 148. Thermo Fisher Scientific Inc.: Company Snapshot
Table 149. Thermo Fisher Scientific Inc.: Product Segments
Table 150. Thermo Fisher Scientific Inc.: Product Portfolio
Table 151. Abbott Laboratories: Key Executives
Table 152. Abbott Laboratories: Company Snapshot
Table 153. Abbott Laboratories: Product Segments
Table 154. Abbott Laboratories: Product Portfolio
Table 155. Bgi Group: Key Executives
Table 156. Bgi Group: Company Snapshot
Table 157. Bgi Group: Product Segments
Table 158. Bgi Group: Product Portfolio
List of Figures
Figure 01. Prenatal and Newborn Genetic Testing Market, 2021-2031
Figure 02. Segmentation of Prenatal and Newborn Genetic Testing Market, 2021-2031
Figure 03. Top Investment Pockets in Prenatal and Newborn Genetic Testing Market (2022-2031)
Figure 04. Moderate Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. High Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalprenatal and Newborn Genetic Testing Market
Figure 10. Prenatal and Newborn Genetic Testing Market, by Product Type, 2021(%)
Figure 11. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Consumables, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Instruments, by Country 2021-2031(%)
Figure 13. Prenatal and Newborn Genetic Testing Market, by Screening, 2021(%)
Figure 14. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Non-Invasive Prenatal Testing, by Country 2021-2031(%)
Figure 15. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Chronic Villus Sampling, by Country 2021-2031(%)
Figure 16. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Amniocentesis, by Country 2021-2031(%)
Figure 17. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Maternal Serum Screening, by Country 2021-2031(%)
Figure 18. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Others, by Country 2021-2031(%)
Figure 19. Prenatal and Newborn Genetic Testing Market, by Disease, 2021(%)
Figure 20. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Downs Syndrome, by Country 2021-2031(%)
Figure 21. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Phenylketonuria, by Country 2021-2031(%)
Figure 22. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Cystic Fibrosis, by Country 2021-2031(%)
Figure 23. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Sickle Cell Anemia, by Country 2021-2031(%)
Figure 24. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Others, by Country 2021-2031(%)
Figure 25. Prenatal and Newborn Genetic Testing Market, by End-user, 2021(%)
Figure 26. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Hospital, by Country 2021-2031(%)
Figure 27. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Maternity and Specialty Clinics, by Country 2021-2031(%)
Figure 28. Comparative Share Analysis of Prenatal and Newborn Genetic Testing Market for Diagnostic Centers, by Country 2021-2031(%)
Figure 29. Prenatal and Newborn Genetic Testing Market by Region, 2021
Figure 30. U.S. Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 31. Canada Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 32. Mexico Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 33. Germany Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 34. France Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 35. UK Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 36. Italy Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 37. Spain Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 38. Rest of Europe Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 39. Japan Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 40. China Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 41. Australia Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 42. India Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 43. South Korea Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 44. Rest of Asia-Pacific Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 45. Brazil Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 46. Saudi Arabia Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 47. South Africa Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 48. Rest of LAMEA Prenatal and Newborn Genetic Testing Market, 2021-2031 ($Million)
Figure 49. Top Winning Strategies, by Year
Figure 50. Top Winning Strategies, by Development
Figure 51. Top Winning Strategies, by Company
Figure 52. Product Mapping of Top 10 Players
Figure 53. Competitive Dashboard
Figure 54. Competitive Heatmap: Prenatal and Newborn Genetic Testing Market
Figure 55. Top Player Positioning, 2021
Figure 56. Bio-Rad Laboratories, Inc.: Net Revenue, 2019-2021 ($Million)
Figure 57. Bio-Rad Laboratories, Inc.: Revenue Share by Segment, 2021 (%)
Figure 58. Bio-Rad Laboratories, Inc.: Revenue Share by Region, 2021 (%)
Figure 59. Perkinelmer Inc.: Net Revenue, 2019-2021 ($Million)
Figure 60. Perkinelmer Inc.: Revenue Share by Segment, 2021 (%)
Figure 61. Perkinelmer Inc.: Revenue Share by Region, 2019 (%)
Figure 62. Natera, Inc.: Net Sales, 2019-2021 ($Million)
Figure 63. Natera, Inc.: Revenue Share by Region, 2021 (%)
Figure 64. Quest Diagnostics Incorporated: Net Revenue, 2019-2021 ($Million)
Figure 65. F. Hoffmann-La Roche AG: Net Revenue, 2019-2021 ($Million)
Figure 66. F. Hoffmann-La Roche AG: Revenue Share by Segment, 2021 (%)
Figure 67. Mettler Toledo: Net Revenue, 2019-2021 ($Million)
Figure 68. Mettler Toledo: Revenue Share by Region, 2021 (%)
Figure 69. Laboratory Corporation of America Holdings: Net Revenue, 2019-2021 ($Million)
Figure 70. Laboratory Corporation of America Holdings: Revenue Share by Segment, 2021 (%)
Figure 71. Laboratory Corporation of America Holdings: Revenue Share by Region, 2021 (%)
Figure 72. Thermo Fisher Scientific Inc.: Net Revenue, 2019-2021 ($Million)
Figure 73. Thermo Fisher Scientific Inc.: Revenue Share by Segment, 2021 (%)
Figure 74. Thermo Fisher Scientific Inc.: Revenue Share by Region, 2021 (%)
Figure 75. Abbott Laboratories: Net Sales, 2019-2021 ($Million)
Figure 76. Abbott Laboratories: Revenue Share by Segment, 2021 (%)
Figure 77. Abbott Laboratories: Revenue Share by Region, 2021 (%)
Executive Summary
According to the report titled, 'Prenatal and Newborn Genetic Testing Market,' the prenatal and newborn genetic testing market was valued at $4,891.51 million in 2021 and is estimated to reach $14,727.30 million by 2031, exhibiting a CAGR of 11.5% from 2022 to 2031.Prenatal and newborn genetic screening are the tests performed during pregnancy and after the birth of newborns. These tests are performed to detect any genetic diseases or chromosomal abnormalities in an early stage of pregnancy and as soon as after the birth of a newborn. Prenatal and newborn screening detect congenital abnormalities including, Down’s syndrome, phenylketonuria, sickle cell anemia, and others. These tests are performed by using PCR, spectrophotometer, and non-invasive prenatal testing.
Key factors driving the growth of the prenatal and newborn genetic testing market include an increase in awareness for early disease diagnosis by using various prenatal and newborn genetic tests and a rise in initiatives taken by the government to implement newborn screening in healthcare facilities. For instance, the State Public Health department of the U.S. manages each state’s newborn screening program, which is designed to ensure that all newborns should receive diagnostic testing for genetic disorders. In addition, according to the American College of Obstetricians and Gynecologists, newborn screening is the most extensive genetic screening program in the U.S., with approximately 4 million infants screened annually. The goal of this public health program is to decrease mortality by screening for disorders which will enhance health outcomes. In this screening program, the most common conditions diagnosed by newborn screening are medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, Down’s syndrome, primary congenital hypothyroidism, cystic fibrosis, and others. Therefore, a rise in government initiatives and awareness of prenatal and newborn screening boosts the growth of the market.
In addition, the National Library of Medicine estimated that phenylketonuria occurs in 1 in 10,000 newborns. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), in May 2022, sickle cell disease occurs in 1 out of 365 African and American births. Furthermore, the rise in technological advancement is the key factor that boosts market growth. For instance, in August 2022, F. Hoffmann-La Roche AG launched the Digital LightCycler System a next-generation digital PCR system that helps physicians to better understand the nature of genetic diseases. This system is designed for performing highly sensitive and precise RNA and DNA analysis.
The market also offers growth opportunities to the key players in the market. The rise in awareness about minimally invasive prenatal testing in under-developed and developing countries such as India and China is expected to create lucrative growth opportunities for market growth. Moreover, the rise in disposable income in India and China also contributes toward the market growth during the forecast period. In addition, an increase in the number of genetic screenings of pregnant women and newborn babies, growth in the number of healthcare policies for genetic testing, and the adoption of non-invasive prenatal testing (NIPT) in developed and developing countries are expected to create growth opportunities for the prenatal and newborn genetic testing market. Furthermore, non-invasive prenatal testing (NIPT) became available in Germany as a publicly reimbursed test in 2022 which is expected to increase prenatal testing during the forecast period.
Moreover, the increase in the prevalence of genetic diseases including Edward syndrome, Patau syndrome, and Down’s syndrome in newborns and the rise in demand for genetic testing in the prenatal and newborn populations are the key factors that drive the market growth. For instance, the data published by the Centers for Disease Control and Prevention (CDC), in November 2022, each year about 6,000 babies born in the U.S. have Down syndrome. Thus, rise in the prevalence of genetic diseases increases the demand for prenatal and newborn testing, which, in turn, contributes to the growth of the market.
The prenatal and newborn genetic testing market is segmented into product type, screening, disease, and end user. On the basis of product type the market is bifurcated into instruments and consumables. On the basis of screening, the market is segmented into non-invasive prenatal testing (NIPT), chronic villus sampling (CVS), amniocentesis, maternal serum screening (MSS), and others. On the basis of disease, the market is categorized into Down’s syndrome, phenylketonuria, cystic fibrosis, sickle cell anemia, and others. On the basis of end user, the market is fragmented into hospitals, maternity and specialty clinics, and diagnostic centers. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia, Portugal and the rest of Europe), Asia-Pacific (China, India, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Argentina, South Africa, and rest of LAMEA).
The key players profiled in the study include Bio-Rad Laboratories, Inc., PerkinElmer Inc., Natera, Inc., Quest Diagnostics Incorporated, F. Hoffmann-La Roche AG, Mettler Toledo, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Abbott Laboratories, and BGI Group.
Companies Mentioned
- Bio-Rad Laboratories, Inc.
- Mettler Toledo
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- BGI Group
- PerkinElmer Inc.
- Natera, Inc.
- F. Hoffmann-La Roche AG
- Quest Diagnostics Incorporated
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
